Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
Nuvation Bio Inc. (NYSE: NUVB) has appointed Philippe Sauvage as Chief Financial Officer. With over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations, Sauvage joins Nuvation Bio as the company prepares to transition into a commercial-stage organization.
Sauvage's most recent role was Global Head of Operations and Access at Sanofi, where he oversaw strategic segments including commercial systems, multichannel strategy, and market access. He previously served as CFO for Sanofi-Genzyme and Sanofi North America, managing a $14 billion region. His experience also includes roles as CFO in Sanofi's JPAC region and Japan, as well as leadership positions in the French public health sector and Ministry of Health.
David Hung, M.D., Founder, President, and CEO of Nuvation Bio, expressed excitement about Sauvage joining the company, highlighting his broad skillset and strategic vision as invaluable for Nuvation Bio's transition to a commercial-stage organization in 2025.
Nuvation Bio Inc. (NYSE: NUVB) ha nominato Philippe Sauvage come Direttore Finanziario. Con oltre 20 anni di esperienza nella leadership globale in finanza, operazioni e commercializzazione all'interno di organizzazioni sanitarie e biofarmaceutiche, Sauvage si unisce a Nuvation Bio mentre l'azienda si prepara a transire verso uno stadio commerciale.
Il ruolo più recente di Sauvage è stato quello di Global Head of Operations and Access presso Sanofi, dove ha supervisionato segmenti strategici tra cui sistemi commerciali, strategia multicanale e accesso al mercato. Ha precedentemente ricoperto il ruolo di CFO per Sanofi-Genzyme e Sanofi Nord America, gestendo una regione da 14 miliardi di dollari. La sua esperienza include anche ruoli come CFO nella regione JPAC di Sanofi e in Giappone, oltre a posizioni di leadership nel settore sanitario pubblico francese e al Ministero della Salute.
David Hung, M.D., Fondatore, Presidente e CEO di Nuvation Bio, ha espresso entusiasmo per l'arrivo di Sauvage in azienda, evidenziando il suo ampio set di competenze e la visione strategica come elementi preziosi per la transizione di Nuvation Bio a un'organizzazione in fase commerciale nel 2025.
Nuvation Bio Inc. (NYSE: NUVB) ha nombrado a Philippe Sauvage como Director Financiero. Con más de 20 años de experiencia en liderazgo global en finanzas, operaciones y comercialización dentro de organizaciones de salud y biofarmacéuticas, Sauvage se une a Nuvation Bio mientras la empresa se prepara para hacer la transición a una organización en etapa comercial.
El rol más reciente de Sauvage fue el de Jefe Global de Operaciones y Acceso en Sanofi, donde supervisó segmentos estratégicos, incluyendo sistemas comerciales, estrategia multicanal y acceso al mercado. Anteriormente, fue CFO de Sanofi-Genzyme y Sanofi Norteamérica, gestionando una región de 14 mil millones de dólares. Su experiencia también incluye roles como CFO en la región JPAC de Sanofi y en Japón, así como puestos de liderazgo en el sector de salud pública francés y en el Ministerio de Salud.
David Hung, M.D., Fundador, Presidente y CEO de Nuvation Bio, expresó su entusiasmo por la incorporación de Sauvage a la empresa, destacando que su amplio conjunto de habilidades y visión estratégica son invaluables para la transición de Nuvation Bio a una organización en fase comercial en 2025.
Nuvation Bio Inc. (NYSE: NUVB)가 Philippe Sauvage를 최고재무책임자(CFO)로 임명했습니다. 20년 이상의 글로벌 리더십 경험을 가진 Sauvage는 건강 관리 및 생명공학 조직에서 재무, 운영 및 상용화 분야에서 경험을 쌓았습니다. 그는 Nuvation Bio에 합류하여 회사가 상업 단계 조직으로 전환할 준비를 하고 있습니다.
Sauvage의 최근 역할은 Sanofi에서 글로벌 운영 및 접근 담당 책임자로서 상업 시스템, 다채널 전략 및 시장 접근과 같은 전략적 세그먼트를 감독했습니다. 그는 이전에 Sanofi-Genzyme 및 Sanofi 북미의 CFO로 재직하면서 140억 달러 규모의 지역을 관리했습니다. 그의 경험에는 Sanofi의 JPAC 지역 및 일본에서 CFO 역할과 프랑스 공공 보건 부문 및 보건부에서의 리더십 역할도 포함됩니다.
Nuvation Bio의 설립자, 사장 및 CEO인 David Hung, M.D.는 Sauvage가 회사에 합류하게 된 것에 대해 흥분을 표시하며 그의 폭넓은 기술 세트와 전략적 비전이 Nuvation Bio의 2025년 상업 단계 조직으로의 전환에 매우 귀중하다고 강조했습니다.
Nuvation Bio Inc. (NYSE: NUVB) a nommé Philippe Sauvage au poste de Directeur Financier. Fort de plus de 20 ans d'expérience en leadership mondial dans les domaines des finances, des opérations et de la commercialisation au sein d'organisations de santé et bio-pharmaceutiques, Sauvage rejoint Nuvation Bio alors que l'entreprise se prépare à passer à une organisation en phase commerciale.
Le rôle le plus récent de Sauvage était celui de Directeur mondial des opérations et de l'accès chez Sanofi, où il supervisait des segments stratégiques comprenant des systèmes commerciaux, des stratégies multicanaux et l'accès au marché. Il a précédemment occupé le poste de CFO pour Sanofi-Genzyme et Sanofi Amérique du Nord, gérant une région de 14 milliards de dollars. Son expérience comprend également des postes de CFO dans la région JPAC de Sanofi et au Japon, ainsi que des postes de direction dans le secteur de la santé publique français et au ministère de la Santé.
David Hung, M.D., Fondateur, Président et CEO de Nuvation Bio, a exprimé son enthousiasme pour l'arrivée de Sauvage dans l'entreprise, soulignant que son large éventail de compétences et sa vision stratégique sont inestimables pour la transition de Nuvation Bio vers une organisation à un stade commercial en 2025.
Nuvation Bio Inc. (NYSE: NUVB) hat Philippe Sauvage zum Finanzvorstand ernannt. Mit über 20 Jahren globaler Führungserfahrung in den Bereichen Finanzen, Betrieb und Vermarktung in Gesundheits- und Biopharma-Organisationen tritt Sauvage Nuvation Bio bei, während das Unternehmen sich auf den Übergang zu einer Organisation in der kommerziellen Phase vorbereitet.
Sauvages letzte Position war Global Head of Operations and Access bei Sanofi, wo er strategische Segmente wie kommerzielle Systeme, Multichannel-Strategien und Marktzugang überwachte. Zuvor war er CFO von Sanofi-Genzyme und Sanofi Nordamerika und verwaltete eine Region von 14 Milliarden Dollar. Zu seiner Erfahrung gehören auch CFO-Rollen in Sanofis JPAC-Region und Japan sowie Führungspositionen im französischen Gesundheitssektor und im Gesundheitsministerium.
David Hung, M.D., Gründer, Präsident und CEO von Nuvation Bio, äußerte sich begeistert über Sauvages Einstieg in das Unternehmen und betonte, dass sein breites Kompetenzspektrum und seine strategische Vision von unschätzbarem Wert für den Übergang von Nuvation Bio zu einer kommerziellen Organisation im Jahr 2025 seien.
- Appointment of an experienced CFO with 20+ years of global leadership in finance, operations, and commercialization
- New CFO's expertise in commercial systems, multichannel strategy, and market access
- Preparation for transition to a commercial-stage organization by 2025
- Potential commercialization of taletrectinib in the pipeline
- None.
Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization
Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multichannel strategy, and market access—key factors in supporting market growth and product launches. Mr. Sauvage previously served as CFO for Sanofi-Genzyme and Sanofi North America, where he led the financial operations for all
“We are excited to welcome Philippe to Nuvation Bio at such an important stage of our evolution,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “Philippe has successfully driven growth and led finance and operations teams across
“I am thrilled to join Nuvation Bio as the team prepares for the potential commercialization of taletrectinib and advances its differentiated oncology pipeline,” said Mr. Sauvage. “I look forward to working alongside David and the entire team to deliver better treatment options to people living with difficult-to-treat cancers.”
Mr. Sauvage holds a Research Masters in Macroeconomics from Panthéon-Sorbonne University in
About Nuvation Bio
Nuvation Bio is a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in
Forward Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, our expectations and timing of establishing a commercial organization. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; competitive developments; and establishing commercial capabilities. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on August 5, 2024, under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241007470241/en/
Nuvation Bio Investor Contact:
ir@nuvationbio.com
Nuvation Bio Media Contact:
media@nuvationbio.com
Source: Nuvation Bio Inc.
FAQ
Who is the new CFO of Nuvation Bio (NUVB)?
What is Philippe Sauvage's background before joining Nuvation Bio (NUVB)?
When does Nuvation Bio (NUVB) plan to transition to a commercial-stage organization?
What potential product is Nuvation Bio (NUVB) preparing to commercialize?
